Repligen Corporation (RGEN)
RGENNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$173.98
-4.96 (-2.77%) today
At the close, Nov 10, 4:00 PM ET. After hours $173.98 –
- Market cap
- $11.12bn
- P/E
- 85.3
- EPS, last 4 quarters
- $2.04
- Dividend yield
- –
- Day range
- $173.87 to $178.37
- 52-week range
- $100.99 to $198.87
- Average volume
- 1.24m
- Previous close
- $178.94
Analysts
9 coveringBuy7 buy, 2 hold, 0 sell
Targets a year out average $210.29, +20.9% from here
Earnings
next estimate $0.5300Next report
Dec 2025
+11.4%
Mar 2026
+26.3%
Jun 2026
+20.0%
Sep 2026
+15.2%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $197.91m | $194.25m | $204.13m | $209.31m |
| Gross profit | $101.36m | $108.28m | $110.04m | $110.99m |
| Operating income | $17.87m | $15.94m | $13.98m | -$29.55m |
| Net income | $13.29m | $8.33m | $5.01m | -$38.43m |
Last four quarters: revenue $805.61m, margin -1.5%, free cash flow $106.72m
News
8 latest- Repligen Corporation Issues $1.0 Billion of 0.25% Convertible Senior Notes due 2031Fintel · 4 days ago
- Repligen: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · 5 days ago
- Repligen Announces $1 Bln Convertible Notes Offering To Extend Debt Maturity RTTNews · Oct 30, 2026
- Repligen (RGEN) Q3 2026 Earnings Call TranscriptThe Motley Fool · Oct 27, 2026
- What Repligen (RGEN) Said on Its Q3 Earnings CallMarketBeat · Oct 27, 2026
- Repligen Corporation Reports Third Quarter 2026 Revenue of $209 millionFintel · Oct 27, 2026
- Repligen (RGEN) Q3 Earnings and Revenues Surpass EstimatesZacks · Oct 27, 2026
- Repligen Corp Completes Acquisition Of BioLife Solutions RTTNews · Oct 7, 2026
The company
Repligen Corporation is a global bioprocessing company that develops and commercializes innovative technologies and integrated solutions that support critical steps in the manufacturing and delivery of biologic drugs that improve human health worldwide. As a trusted partner to biopharmaceutical developers and manufacturers and CDMOs worldwide, we help improve productivity, simplify complex workflows, and advance the next generation of biologic therapies. Repligen technologies support the production of a broad range of biologic modalities, helping customers navigate evolving manufacturing challenges from process development through commercial production. Our global team combines deep scientific expertise, innovation, and a customer-focused mindset 'inspiring advances in bioprocessing' to help solve complex challenges across biologics manufacturing.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- repligen.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.